Qilu first imitation kidney cell carcinoma drug "Peeppelpani tablets" declared to be listed to obtain CDE acceptance

Renecell carcinoma is a common malignant tumor in the world, the morbidity and mortality rate accounts for about 2%-3% of systemic tumors, in the urinary system malignancies, the incidence of the incidence is second only to bladder cancer, and is increasing year by yearRecently, according to theNew Drug(http://Research and Development Monitoring Database (CPM) shows that Qilu first imitation renal cell carcinomadrug(http://"Periphpantablets" declared to be accepted by CDEabout theof PeppaniPazopanib, Votrient, an vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor developed by GSK, was packaged and transferred to Novartis in 2014 in the GSK and Novartis asset replacement transactions for patients with advanced renal cell carcinoma and advanced soft tissue sarcomaThe mechanism of perezoli's role is similar to that of Sorafeni, Schonitinib and Axidine, and was approved by theFDA(http://and the EUROPEAN Union EMA on October 20, 2009 and June 15, 2010, respectivelyThe incidence of serious adverse reactions is very low, NCCN, EAU, ESMO, CSCO guidelines are recommended in 1 kind of evidence for the standard treatment of advanced kidney cancer 　　Has been approved in more than 100 countries and regions around the world for the treatment of advanced renal cell carcinoma 　　In clinical studies, Peppapani has conducted three large-scale clinical trials (http:// , and is the first targeted drug to conduct a horizontal head-to-head clinical study of all advanced kidney cancer strap